BridgeBio Pharma, Inc.
BBIONASDAQHealthcare● Active
$67.37
$-0.24(-0.35%)
Market Cap$13.2B
P/E Ratio—
52W High$84.94
52W Low$38.575
BridgeBio Pharma, Inc. (BBIO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BBIO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.72B) | ($0.54B) | ($0.64B) | ($0.48B) | ($0.59B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Stock-Based Comp. | $0.13B | $0.10B | $0.00B | $0.09B | $0.10B |
| Change in Working Capital | ($0.05B) | $0.03B | $0.01B | $0.03B | ($0.00B) |
| Net Cash from Operations | ($0.45B) | ($0.52B) | ($0.53B) | ($0.42B) | ($0.50B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.01B) | ($0.05B) |
| Purchases of Investments | ($0.03B) | ($0.09B) | ($0.14B) | ($0.19B) | ($0.64B) |
| Sales of Investments | $0.01B | $0.16B | $0.19B | $0.53B | $0.48B |
| Net Cash from Investing | ($0.02B) | $0.06B | $0.05B | $0.45B | ($0.20B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.05B) | ($0.01B) | ($0.01B) | ($0.00B) | ($0.20B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.39B | $0.48B | $0.00B | ($0.02B) | $1.08B |
| Net Cash from Financing | $0.36B | $0.75B | $0.45B | ($0.01B) | $0.74B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.45B) | ($0.52B) | ($0.53B) | ($0.43B) | ($0.55B) |
| FCF Margin %(computed) | -89.03% | -235.09% | — | -548.39% | -783.44% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more BridgeBio Pharma, Inc. data
About BridgeBio Pharma, Inc. (BBIO) Cash Flow Statement
BridgeBio Pharma, Inc. generated operating cash flow of ($0.45B) and free cash flow of ($0.45B) for 2025 — a FCF margin of -89.03%. Capital expenditure was ($0.00B).
Frequently asked questions
BBIO · 4 questionsBridgeBio Pharma, Inc. generated free cash flow of ($0.45B) for 2025, up 14.3% year-over-year.
BBIO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10